Miraqules, a biotechnology company based in Bengaluru, is set to showcase its innovative blood clotting technology at the upcoming TechCrunch Disrupt 2025 event. The company has developed a nanotechnology in powder form, designed to mimic blood clotting proteins, which could have significant implications for trauma care. The event will take place in San Francisco from October 27 to 29, 2025.
Co-founder and CEO Sabir Hossain draws inspiration from a personal experience when developing this life-saving technology. After a near-tragic incident involving his father, who suffered severe bleeding, Hossain was determined to create a solution that could provide immediate assistance in emergency situations. The powder created by Miraqules has the ability to rapidly produce fibrous compounds at room temperature, effectively absorbing blood quickly when applied.
“This is a product that will give you feedback instantly,” Hossain explained. “If there is a person bleeding, you apply it, and the bleeding stops. This whole thing happens within one or two minutes.”
From Research to Reality
Hossain’s journey into the world of biotechnology began in graduate school, where he focused on biomedical engineering. During his time in a research lab centered on biomaterials, he encountered challenges while attempting to synthesize materials that promote bone tissue growth.
“I was really bad at that, actually,” Hossain admitted. “Every time I was synthesizing that material, it was getting dismantled.”
One day, he repurposed the dismantled particles into a powder and presented it to a team working on blood clotting solutions that were struggling with their mixing processes. The results were impressive; the compound clotted blood within five to ten seconds.
“I rushed to my professor and then from there we started to think about what made it happen,” he recalled. “We came up with a completely new process of combining off-the-shelf materials into a nanomaterial that mimics blood clotting proteins.”
Hossain partnered with his childhood friend, Mubeen Midda, to further develop the technology and transition it from the lab to practical applications. With minimal funding, the duo has secured 11 patents across seven countries, including India, the United States, and Israel.
Regulatory Approvals and Future Plans
Miraqules is currently piloting its technology at a trauma care center in India, with expectations of receiving regulatory clearance in the country within the coming months. The company is also pursuing approval from the U.S. Food and Drug Administration, with hopes of achieving this milestone by 2026.
“One thing we did from the beginning was directly approach the U.S. FDA,” Hossain noted. “There is something called pre-submission. We tried to get their feedback on what other necessary things we need to do to get this product approved, and that helped us a lot.”
The company has reached these key milestones with less than $700,000 in capital raised, primarily through grants. As Miraqules looks to expand its deployment and pilot programs in the upcoming year, it has garnered interest from ten different hospital chains in India and the Israeli Defense Forces.
For those interested in learning more about Miraqules and witnessing additional innovative pitches, TechCrunch Disrupt 2025 promises a platform for startups to connect and share their breakthroughs. With over 300 startups showcasing their technologies and insights from more than 250 industry leaders, the event is poised to drive significant advancements in the startup ecosystem.
Attendees can register to participate from October 27 to 29 in San Francisco, with opportunities for networking and workshops designed to foster business growth.
